DK2783697T3 - VIP-Fragmenter og anvendelser deraf - Google Patents

VIP-Fragmenter og anvendelser deraf Download PDF

Info

Publication number
DK2783697T3
DK2783697T3 DK14170486.6T DK14170486T DK2783697T3 DK 2783697 T3 DK2783697 T3 DK 2783697T3 DK 14170486 T DK14170486 T DK 14170486T DK 2783697 T3 DK2783697 T3 DK 2783697T3
Authority
DK
Denmark
Prior art keywords
vip
composition
lys
myocardial fibrosis
prt
Prior art date
Application number
DK14170486.6T
Other languages
English (en)
Inventor
Karen Annette Duggan
Original Assignee
Vectus Biosystems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38122420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2783697(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2005906947A external-priority patent/AU2005906947A0/en
Application filed by Vectus Biosystems Ltd filed Critical Vectus Biosystems Ltd
Application granted granted Critical
Publication of DK2783697T3 publication Critical patent/DK2783697T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Claims (13)

1. Sammensætning omfattende en farmaceutisk effektiv mængde af ét eller flere funktionelle vasoaktive intestinale peptid-(VIP)-fragmenter valgt fra gruppen bestående af: VIP(6-16), VIP(6-20), VIP(6-24) og konservative substitutioner deraf, som ikke ændrer den biologiske aktivitet for peptidet.
2. Sammensætning ifølge krav 1, til anvendelse ved terapeutisk eller profylaktisk behandling af myocardial fibrose.
3. Sammensætning til anvendelse ved terapeutisk eller profylaktisk behandling af hypertension, hvilken sammensætning omfatter ét eller flere VIP-fragmenter valgt fra gruppen bestående af VIP(6-20), VIP(6-24) og konservative substitutioner deraf, som ikke ændrer den biologiske aktivitet for peptidet.
4. Sammensætning til anvendelse ved profylaktisk eller terapeutisk behandling af hypertension i en patient med myocardial fibrose, hvilken sammensætning omfatter ét eller flere VIP-fragmenter valgt fra gruppen bestående af VIP(6-20), VIP(6-24) og konservative substitutioner deraf, som ikke ændrer den biologiske aktivitet for peptidet.
5. Sammensætning til anvendelse ifølge krav 4, hvor hypertensionen er knyttet til myocardial fibrose.
6. Sammensætning ifølge krav 1, eller en sammensætning til anvendelse ifølge ethvert af kravene 2-5, indgivet i forbindelse med et farmaceutisk acceptabelt bærestof.
7. Sammensætning ifølge krav 1, eller en sammensætning til anvendelse ifølge ethvert af kravene 2-6, indgivet i forbindelse med ét eller flere yderligere aktive midler, som er nyttige ved behandling af cardiovaskulære tilstande.
8. Sammensætning ifølge krav 1, eller en sammensætning til anvendelse ifølge ethvert af kravene 2-7, formuleret til indgivelse oralt, intravenøst, intramuskulært eller subkuti-kulært.
9. Sammensætning til anvendelse ifølge krav 2, hvor sammensætningen forhindrer eller forsinker progressionen af etableret myocardial fibrose.
10. Sammensætning til anvendelse ifølge krav 2, hvor sammensætningen reducerer graden af etableret fibrose.
11. Sammensætning til anvendelse ifølge krav 2, hvor sammensætningen er til anvendelse ved behandling af én eller flere tilstande knyttet til myocardial fibrose, valgt blandt hypertension, diabetes, myocarditis, iskæmisk hjertesygdom, venstreventrikulær hypertrofi, diastolisk dysfunktion, cardiomyopati, venstreventrikulær dysfunktion, konge-stivt hjertesvigt, behandling med medikamenter anvendt ved cancerkemoterapi, genetisk prædisposition, Conn's syndrom, Phaeochromocytom og højt saltindtag.
12. Sammensætning til anvendelse ifølge krav 11, hvor tilstandene knyttet til myocardial fibrose omfatter tilstande, som forårsager generering af profibrotiske mediatorer eller tilstande, som prædisponerer et subjekt for myocardial fibrose.
13. Sammensætning til anvendelse ved sænkning af blodtryk, hvilken sammensætning omfatter ét eller flere VIP-fragmenter valgt fra gruppen bestående af VIP(6-20), VIP(6-24), og konservative substitutioner deraf, som ikke ændrer den biologiske aktivitet for peptidet.
DK14170486.6T 2005-12-09 2006-12-08 VIP-Fragmenter og anvendelser deraf DK2783697T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2005906947A AU2005906947A0 (en) 2005-12-09 VIP fragments and methods of use
EP06817603.1A EP1976548B1 (en) 2005-12-09 2006-12-08 VIP fragments and compositions thereof

Publications (1)

Publication Number Publication Date
DK2783697T3 true DK2783697T3 (da) 2017-04-10

Family

ID=38122420

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14170486.6T DK2783697T3 (da) 2005-12-09 2006-12-08 VIP-Fragmenter og anvendelser deraf
DK06817603.1T DK1976548T3 (da) 2005-12-09 2006-12-08 VIP-fragmenter og sammensætninger deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK06817603.1T DK1976548T3 (da) 2005-12-09 2006-12-08 VIP-fragmenter og sammensætninger deraf

Country Status (20)

Country Link
US (4) US8470778B2 (da)
EP (2) EP2783697B1 (da)
JP (3) JP5449778B2 (da)
KR (2) KR101404561B1 (da)
CN (2) CN101325964B (da)
AR (2) AR058308A1 (da)
AU (1) AU2006322656B2 (da)
BR (1) BRPI0620566B8 (da)
CA (2) CA2952475C (da)
DK (2) DK2783697T3 (da)
ES (2) ES2523858T3 (da)
HK (1) HK1122746A1 (da)
IL (3) IL192046A (da)
NZ (4) NZ597677A (da)
PL (1) PL1976548T3 (da)
PT (1) PT1976548E (da)
RU (1) RU2466738C2 (da)
TW (1) TWI402273B (da)
WO (1) WO2007065226A1 (da)
ZA (1) ZA200805837B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4824682B2 (ja) * 2004-06-11 2011-11-30 ベクタス・バイオシステムズ・リミテッド 循環器病の治療のための組成物および方法
ES2638792T3 (es) * 2005-07-28 2017-10-24 Carbon Sink Inc. Eliminación de dióxido de carbono del aire
NZ597677A (en) 2005-12-09 2013-05-31 Vectus Biosystems Ltd Vip fragments and methods of use
WO2007073486A2 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
EP2307038A4 (en) 2008-06-27 2013-03-27 Univ Duke THERAPEUTIC AGENTS COMPRISING ELASTINE-LIKE PEPTIDES
DK2349320T3 (da) 2008-10-17 2016-09-26 Vectus Biosystems Ltd Sammensætninger og fremgangsmåder til behandling af nyrelidelser
CN101434649B (zh) * 2008-12-12 2012-04-25 余榕捷 一种环七肽及其制备方法和应用
US8729020B2 (en) * 2009-04-02 2014-05-20 Vectus Biosystems Pty Ltd Methods for the treatment of aortic fibrosis with VIP fragments
ES2870914T3 (es) * 2009-08-14 2021-10-28 Phasebio Pharmaceuticals Inc Péptidos intestinales vasoactivos modificados
CA2873553C (en) 2011-06-06 2020-01-28 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
UA118111C2 (uk) * 2013-09-17 2018-11-26 Вектус Байосистемз Лімітед Сполука та композиція для лікування гіпертензії та/або фіброзу
US9375638B2 (en) * 2014-01-02 2016-06-28 Lloyd A. Weaver Game console switch box
ES2818824T3 (es) 2014-05-08 2021-04-14 Phasebio Pharmaceuticals Inc Composiciones que comprenden una proteína de fusión de VIP-ELP para su uso en el tratamiento de fibrosis quística
ES2822598T3 (es) 2015-02-09 2021-05-04 Phasebio Pharmaceuticals Inc Métodos y composiciones para tratar enfermedades y trastornos musculares

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862927A (en) * 1973-02-26 1975-01-28 Sami I Said Process for preparation of vasoactive intestinal peptide
US4016258A (en) * 1975-08-05 1977-04-05 Said Sami I Vasoactive intestinal peptide from fowl
US4237046A (en) * 1979-04-27 1980-12-02 Miklos Bodanszky Polypeptides and methods of preparation
GB8427651D0 (en) * 1984-11-01 1984-12-05 Beecham Group Plc Compounds
NZ221440A (en) * 1986-08-20 1991-11-26 Genetic Systems Corp Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections
US5972883A (en) * 1993-03-16 1999-10-26 Yeda Research And Development Co. Ltd. Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof
US5808037A (en) * 1995-09-15 1998-09-15 Ramareddy Venkata Guntaka Oligomers which inhibit expression of collagen genes
US20020115609A1 (en) * 1997-07-14 2002-08-22 Hayat Onyuksel Materials and methods for making improved micelle compositions
US5892162A (en) * 1997-11-18 1999-04-06 Southwest Research Institute Apparatus and method for inspection of pipes and tubes using guided wave probe
DE60042611D1 (de) * 1999-10-29 2009-09-03 Nitromed Inc Verfahren zur behandlung von gefässerkrankungen, dxid auszeichnen
CA2395165C (en) * 2000-10-20 2012-05-22 Mario Ehlers Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
CN101229363A (zh) * 2000-11-28 2008-07-30 蒙多生物技术许可股份公司 具有血管活性肠肽的生物学活性的用于治疗肺动脉和小动脉高压的化合物
US6911430B2 (en) * 2003-10-01 2005-06-28 Vipogen, Llc Compositions and methods for treating ileus
WO2006038916A2 (en) * 2004-05-21 2006-04-13 Accu-Break Technologies, Inc. Scored pharmaceutical tablets comprising a plurality of segments
CA2567635A1 (en) * 2004-05-21 2005-12-01 Eli Lilly And Company Selective vpac2 receptor peptide agonists
JP4824682B2 (ja) * 2004-06-11 2011-11-30 ベクタス・バイオシステムズ・リミテッド 循環器病の治療のための組成物および方法
NZ597677A (en) * 2005-12-09 2013-05-31 Vectus Biosystems Ltd Vip fragments and methods of use
US20100044560A1 (en) * 2006-07-06 2010-02-25 Franco Basile Method and Apparatus for Pyrolysis-Induced Cleavage in Peptides and Proteins
DK2349320T3 (da) * 2008-10-17 2016-09-26 Vectus Biosystems Ltd Sammensætninger og fremgangsmåder til behandling af nyrelidelser
US8729020B2 (en) * 2009-04-02 2014-05-20 Vectus Biosystems Pty Ltd Methods for the treatment of aortic fibrosis with VIP fragments

Also Published As

Publication number Publication date
EP2783697A3 (en) 2015-01-07
CA2952475A1 (en) 2007-06-14
AU2006322656B2 (en) 2012-03-08
EP1976548A4 (en) 2012-04-18
EP2783697B1 (en) 2017-01-11
IL192046A (en) 2014-03-31
CN101325964B (zh) 2013-09-18
US20160222078A1 (en) 2016-08-04
IL224609A (en) 2014-05-28
US9340583B2 (en) 2016-05-17
US8916523B2 (en) 2014-12-23
AU2006322656A1 (en) 2007-06-14
US20150065424A1 (en) 2015-03-05
RU2008127877A (ru) 2010-01-20
IL192046A0 (en) 2008-12-29
AR058308A1 (es) 2008-01-30
EP1976548A1 (en) 2008-10-08
BRPI0620566B8 (pt) 2021-05-25
CA2952475C (en) 2022-08-09
JP5847793B2 (ja) 2016-01-27
NZ569401A (en) 2012-03-30
PL1976548T3 (pl) 2015-01-30
WO2007065226A1 (en) 2007-06-14
TW200730538A (en) 2007-08-16
PT1976548E (pt) 2014-10-13
CN101325964A (zh) 2008-12-17
US20130244934A1 (en) 2013-09-19
US20090005315A1 (en) 2009-01-01
ES2523858T3 (es) 2014-12-02
EP1976548B1 (en) 2014-07-02
JP2012229222A (ja) 2012-11-22
ES2621864T3 (es) 2017-07-05
JP2014097994A (ja) 2014-05-29
AR109274A2 (es) 2018-11-14
BRPI0620566B1 (pt) 2018-07-24
CA2632581A1 (en) 2007-06-14
KR101404561B1 (ko) 2014-06-11
CN103450345A (zh) 2013-12-18
NZ623674A (en) 2014-07-25
JP5730820B2 (ja) 2015-06-10
NZ597677A (en) 2013-05-31
IL230534A (en) 2014-12-31
CA2632581C (en) 2017-02-07
US9732136B2 (en) 2017-08-15
ZA200805837B (en) 2009-05-27
BRPI0620566A2 (pt) 2011-11-16
RU2466738C2 (ru) 2012-11-20
DK1976548T3 (da) 2014-10-06
US8470778B2 (en) 2013-06-25
TWI402273B (zh) 2013-07-21
KR20080075551A (ko) 2008-08-18
KR20140041943A (ko) 2014-04-04
HK1122746A1 (en) 2009-05-29
JP5449778B2 (ja) 2014-03-19
JP2009518316A (ja) 2009-05-07
EP2783697A2 (en) 2014-10-01
NZ604248A (en) 2014-07-25
CN103450345B (zh) 2016-04-20

Similar Documents

Publication Publication Date Title
DK2783697T3 (da) VIP-Fragmenter og anvendelser deraf
CA2573439C (en) Compositions and methods for treating myocardial fibrosis comprising vasoactive intestinal peptide
DK2349320T3 (da) Sammensætninger og fremgangsmåder til behandling af nyrelidelser
EP2413954B1 (en) Composition comprising vip or its active fragments for use in treating aortic fibrosis